Altimmune Forecast, price target & analysts
Altimmune Target price 2025 - Analyst rating & recommendation
Altimmune Classifications & Recommendation:
Altimmune Price Target
| Target Price | $18.36 |
| Price | $4.59 |
| Potential |
300.00%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Altimmune 2026 .
The average Altimmune target price is $18.36.
This is
300.00%
register free of charge
$29.40
540.52%
register free of charge
$1.01
78.00%
register free of charge
|
|
| A rating was issued by 14 analysts: 11 Analysts recommend Altimmune to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Altimmune stock has an average upside potential 2026 of
300.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.02 | 0.01 |
| 95.35% | 71.50% | |
| EBITDA Margin | -514,650.00% | -1,751,642.98% |
| 2,565.30% | 240.36% | |
| Net Margin | -475,300.00% | -1,886,529.31% |
| 2,210.67% | 296.91% |
9 Analysts have issued a sales forecast Altimmune 2025 . The average Altimmune sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Altimmune EBITDA forecast 2025. The average Altimmune EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Altimmune Analysts have issued a net profit forecast 2025. The average Altimmune net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.34 | -1.12 |
| 19.28% | 16.42% | |
| P/E | negative | |
| EV/Sales | 49,698.40 |
10 Analysts have issued a Altimmune forecast for earnings per share. The average Altimmune EPS is
This results in the following potential growth metrics and future valuations:
Current Altimmune Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jul 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
